| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| | 20-F | 20-F | 20-F | 20-F | 20-F | 10-K | 10-K | 10-K |
| Revenues: |
| Others | | | | 17.3 | 10.2 | 5.5 | 4.5 | 0.9 |
| Bio pharmaceutical Products | | | | 341.2 | | | | |
| Biomaterial products | 46.0 | 44.7 | | | | | | |
| Other | 457.7 | 422.2 | | | 286.3 | 237.7 | 198.8 | 183.9 |
| Total revenues [+] | 503.7 | 466.9 | 370.4 | 341.2 | 296.5 | 243.3 | 203.4 | 184.8 |
| Products | 503.7 | 466.9 | 370.4 | | | | 203.4 | 184.8 |
| Net interest income | | | | | | | 0.3 | 0.4 |
| Revenue growth [+] | 7.9% | 26.0% | 8.6% | 15.1% | 21.9% | 19.6% | 10.0% | 20.7% |
| Others | | | | 69.7% | 83.6% | 23.0% | 406.1% | -43.3% |
| Biomaterial products | 2.9% | | | | | | | |
| Biopharmaceutical products | 8.4% | 14.0% | | | | | | |
| Cost of goods sold | 174.7 | 146.8 | 125.5 | 124.0 | 106.5 | 80.0 | 65.5 | 58.8 |
| Gross profit | 329.1 | 320.1 | 244.9 | 217.1 | 190.0 | 163.2 | 137.9 | 126.0 |
| Gross margin | 65.3% | 68.6% | 66.1% | 63.6% | 64.1% | 67.1% | 67.8% | 68.2% |
| Selling, general and administrative [+] | 153.7 | 164.4 | 102.5 | 66.2 | 51.4 | 42.8 | 46.7 | 48.5 |
| Sales and marketing | 80.3 | 95.6 | 34.8 | 11.7 | 10.0 | 10.7 | 10.6 | 14.4 |
| General and administrative | 73.4 | 68.8 | 67.7 | 54.5 | 41.4 | 32.1 | 36.1 | 34.0 |
| Research and development | 11.7 | 9.5 | 6.5 | 7.0 | 6.0 | 4.2 | 4.2 | 3.0 |
| Equity in earnings | 1.6 | 2.4 | 3.5 | 2.5 | -1.3 | 8.6 | 2.2 | 2.7 |
| Other operating expenses | | | | | | 5.1 | | |
| EBITDA [+] | 191.5 | 171.8 | 152.3 | 159.2 | 140.3 | 127.6 | 96.6 | 86.0 |
| EBITDA growth | 11.5% | 12.8% | -4.3% | 13.4% | 10.0% | 32.1% | 12.2% | 43.7% |
| EBITDA margin | 38.0% | 36.8% | 41.1% | 46.7% | 47.3% | 52.4% | 47.5% | 46.6% |
| Depreciation | 18.1 | 14.5 | 12.4 | 12.2 | 8.2 | 7.0 | 6.1 | 5.8 |
| EBITA | 173.4 | 157.3 | 139.9 | 147.0 | 132.1 | 120.6 | 90.5 | 80.2 |
| EBITA margin | 34.4% | 33.7% | 37.8% | 43.1% | 44.6% | 49.6% | 44.5% | 43.4% |
| Amortization of intangibles | 8.1 | 8.7 | 0.5 | 0.6 | 0.9 | 0.8 | 1.4 | 3.1 |
| EBIT [+] | 165.2 | 148.5 | 139.4 | 146.4 | 131.3 | 119.8 | 89.1 | 77.2 |
| EBIT growth | 11.2% | 6.6% | -4.8% | 11.5% | 9.6% | 34.5% | 15.5% | 47.7% |
| EBIT margin | 32.8% | 31.8% | 37.6% | 42.9% | 44.3% | 49.3% | 43.8% | 41.7% |
| Interest income, net [+] | 20.8 | 13.4 | 7.0 | 7.6 | 3.8 | 2.9 | 3.3 | 1.6 |
| Interest expense | 0.6 | 0.3 | 0.6 | 0.3 | 1.7 | 3.7 | 1.1 | 1.3 |
| Interest income | 21.3 | 13.7 | 7.6 | 7.8 | 5.6 | 6.6 | 4.4 | 2.9 |
| Other income (expense), net [+] | 5.5 | 4.1 | | -0.1 | | | | 2.3 |
| Gain (loss) on sale of business | | | | -0.1 | | | | |
| Unrealized gain/loss on derivatives | | | | | | | | 1.8 |
| Other | 5.5 | 4.1 | | | | 11.6 | 5.5 | 6.6 |
| Pre-tax income | 191.5 | 166.0 | 146.4 | 153.9 | 135.1 | 122.8 | 92.4 | 81.1 |
| Income taxes | 28.1 | 18.0 | 64.2 | 25.1 | 21.0 | 26.6 | 15.5 | 15.2 |
| Tax rate | 14.7% | 10.9% | 43.8% | 16.3% | 15.5% | 21.7% | 16.8% | 18.7% |
| Minority interest | 24.6 | 19.9 | 14.3 | 24.0 | 25.1 | 25.2 | 22.3 | 20.7 |
| Net income | 138.8 | 128.1 | 67.9 | 104.8 | 89.0 | 70.9 | 54.6 | 45.2 |
| Net margin | 27.6% | 27.4% | 18.3% | 30.7% | 30.0% | 29.2% | 26.9% | 24.5% |
| |
| Basic EPS [+] | $3.59 | $3.63 | $2.48 | $3.90 | $3.48 | $2.90 | $2.07 | $1.73 |
| Growth | -1.0% | 46.1% | -36.4% | 12.2% | 19.8% | 40.4% | 19.6% | 138.0% |
| Diluted EPS [+] | $3.57 | $3.61 | $2.46 | $3.85 | $3.35 | $2.76 | $1.98 | $1.68 |
| Growth | -1.3% | 46.8% | -36.0% | 14.7% | 21.4% | 39.4% | 17.5% | 147.0% |
| |
| Shares outstanding (basic) [+] | 38.7 | 35.3 | 27.4 | 26.8 | 25.6 | 24.4 | 26.4 | 26.2 |
| Growth | 9.5% | 29.0% | 1.9% | 4.9% | 4.8% | -7.5% | 1.0% | 4.5% |
| Shares outstanding (diluted) [+] | 38.9 | 35.4 | 27.6 | 27.2 | 26.6 | 25.7 | 27.6 | 26.8 |
| Growth | 9.8% | 28.4% | 1.3% | 2.6% | 3.4% | -6.8% | 2.7% | 0.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |